Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2003

View Archived Issues

Anticytomegalovirus pyridazinones identified by Bayer researchers

New 5-HT1A receptor ligands discovered at Lundbeck

Aventis claims new KDR inhibitors obtained from natural source

New glucokinase activators under study at AstraZeneca

Novel antidiabetic agents identified at Dr. Reddy's Research Foundation

Advances in Alizyme product development portfolio

No effects on cerebral blood perfusion reported for pravastatin after acute stroke

Eptacog alfa in intracerebral hemorrhage

French team presents novel histamine H3 antagonists

8-Arylquinolines with PDE4-inhibitory activity in Merck pipeline

Neurocrine Biosciences reviews year of significant milestones

Midpoint enrollment reached in Oxytrex study

Progress at Myriad Genetics during second quarter of fiscal 2003

Isis achieves second milestone in Amgen antisense collaboration

Echelon Biosciences awarded grant for cancer and diabetes research

Encouraging results reported for Ontak in steroid-resistant acute GvHD

Phase II trial begins for ISS therapy for asthma

AMD-070 demonstrates promise as a new anti-HIV drug targeting CXCR4

Lorus Therapeutics and NCI to evaluate GTI-2040 in phase II trials

Phase II interim results for GI7DT plus chemotherapy in gastric cancer

Orally available CCR5 antagonist with promise as an anti-HIV candidate

Johnson & Johnson completes acquisition of OraPharma

Debiopharm forms collaboration with Tulane University

Clinically relevant therapeutic window seen for NXY-059 in primate acute stroke model

ImmunoGen highlights key advances in its product pipeline

New data for tenofovir DF plus lamivudine and efavirenz in antiretroviral-naive HIV patients

Evidence of antiretroviral efficacy reported for T-1249 in enfuvirtide-resistant HIV patients

Improved safety and pharmacokinetic profile reported for TMC-114 when combined with ritonavir

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...